Novel α2β1Integrin-Targeted Peptide Probes for Prostate Cancer Imaging

Peptide-based probes for cancer imaging.

Receptors for regulatory peptides are overexpressed in a variety of human cancers. They represent the molecular basis for in vivo imaging with radiolabeled peptide probes. Somatostatin-derived tracers, designed to image the sst2-overexpressing neuroendocrine tumors, have enjoyed almost 2 decades of successful development and extensive clinical applications. More recent developments include seco...

A peptide-targeted MRI contrast agent for cancer molecular imaging

Introduction: Early detection and diagnosis of malignant tumors enable more efficacious cancer treatment at an earlier stage and improvement of cancer patients' survival and quality of the life. Magnetic resonance imaging (MRI) is a powerful imaging modality for cancer detection and diagnosis. However, current clinically used contrast enhanced MRI is not effective for molecular imaging because ...

Development of targeted near-infrared imaging agents for prostate cancer.

Prostate cancer is the most common noncutaneous malignancy affecting men in North America. Radical prostatectomy remains a definitive treatment for prostate cancer. However, prostate surgeries are still performed "blindly" with the extent of tumor infiltration past the margins of the surgery only being determined postoperatively. An imaging modality that can be used during surgery is needed to ...

A Novel In-labeled Anti-PSMA Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer

Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.

Non-invasive accurate detection of prostate cancer is critical for clinical management of the disease. Molecular MRI has a potential for accurate detection of prostate cancer with high spatial resolution. Fibronectin is a hallmark of epithelial-mesenchymal transition occurred in aggressive prostate cancer and highly expressed in malignant tumors. A pentapeptide CREKA targeted contrast agent CRE...